BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang J, Wang B, Sun Z, Xue K. Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura. Exp Ther Med 2019;17:2137-42. [PMID: 30867701 DOI: 10.3892/etm.2019.7196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Vianelli N, Auteri G, Buccisano F, Carrai V, Baldacci E, Clissa C, Bartoletti D, Giuffrida G, Magro D, Rivolti E, Esposito D, Podda GM, Palandri F. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol 2022. [PMID: 35201417 DOI: 10.1007/s00277-022-04786-y] [Reference Citation Analysis]
2 Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020;135:472-90. [PMID: 31756253 DOI: 10.1182/blood.2019003599] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]